XORTX Therapeutics Inc.

Equities

XRTX

CA98420Q3061

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 02:38:51 2024-05-17 pm EDT			5-day change	1st Jan Change
3.35 ^CAD	0.00%		-3.18%	+15.52%

May. 17	XORTX Therapeutics Reprices Warrants Connected With U.S. IPO	MT
May. 17	XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO	MT

XORTX Therapeutics Inc. Appoints Dr. David Macdonald as Chief Technology Officer

January 20, 2022 at 07:00 am EST

XORTX Therapeutics Inc. announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO). Dr. MacDonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies. Prior to XORTX, Dr. MacDonald held positions as CTO and later President of MSI Methylation Sciences Inc.

Latest news about XORTX Therapeutics Inc.

XORTX Therapeutics Reprices Warrants Connected With U.S. IPO	May. 17	MT
XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO	May. 17	MT
XORTX Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal	Apr. 22	MT
XORTX Announces Publication of Key Research in ADPKD	Apr. 22	CI
XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors	Apr. 08	CI
XORTX Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board	Mar. 27	CI
XORTX Therapeutics Provides Update	Mar. 19	MT
XORTX Therapeutics Brief: Has Highlighted "Achievements" of 2023 and Preparations for Registration Clinical Trial	Mar. 19	MT
XORTX Therapeutics Inc. announced a financing transaction	Feb. 14	CI
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease	Jan. 03	MT
XORTX Therapeutics Inc. Submits New Patent for the Treatment of Chronic Kidney Disease	Jan. 03	CI
Correction: -- XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease	Jan. 03	MT
XORTX Therapeutics Inc. Announces Board Changes	Jan. 02	CI
US Equity Markets Close Mixed Thursday After Cooler Inflation Data	Nov. 30	MT
Top Midday Decliners	Nov. 30	MT
XORTX Therapeutics Plans US ATM Offering; Down 19.4%	Nov. 30	MT
XORTX Therapeutics Plans US ATM Offering	Nov. 30	MT
XORTX Therapeutics Brief: Announcing US ATM Offering	Nov. 30	MT
XORTX Therapeutics Says Met Nasdaq Continued Listing Requirements	Nov. 29	MT
XORTX Therapeutics Brief: Says Met Nasdaq Continued Listing Requirements	Nov. 29	MT
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
XORTX Therapeutics Brief: Shares expected to begin trading on a post-consolidation basis on the TSX Venture Exchange and the Nasdaq Capital Market when markets open on or about Tuesday, November 14, 2023	Nov. 10	MT
XORTX Therapeutics Brief: Announcing Share Consolidation	Nov. 08	MT

Chart XORTX Therapeutics Inc.

Duration

Period

More charts

Company Profile

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - Bio International Convention

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.35

Average target price

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XORTX THERAPEUTICS INC.	+15.52%	7.14M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs